Xiuning Le, MD, PhD

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Xiuning Le, MD, PhD, spoke about which patients with advanced non–small cell lung cancer with high MET-amplification could benefit most from tepotinib based on molecular markers.

Xiuning Le, MD, PhD, spoke about the use of ctDNA biomarkers and why research should continue for those with advanced non–small cell lung cancer with high MET-amplification being treated with tepotinib.

Xiuning Le, MD, PhD, spoke about unmet needs in patients with advanced non–small cell lung cancer with high MET-amplifications and why tepotinib may be a good treatment option.